This company has been acquired
Applied Genetic Technologies (AGTC) Stock Overview
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
AGTC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Applied Genetic Technologies Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.39 |
| 52 Week High | US$2.83 |
| 52 Week Low | US$0.23 |
| Beta | 1.58 |
| 1 Month Change | -4.23% |
| 3 Month Change | -1.85% |
| 1 Year Change | -80.89% |
| 3 Year Change | -86.79% |
| 5 Year Change | -89.78% |
| Change since IPO | -97.33% |
Recent News & Updates
AGTC receives positive feedback from FDA for manufacturing facility
Applied Genetic Technologies (NASDAQ:AGTC) said the U.S. Food and Drug Administration had provided favorable feedback on the current Good Manufacturing Practice (cGMP) design of AGTC’s manufacturing facility. The facility will support AGTC’s pipeline, including the late-stage development and potential commercialization of its eye diseases therapy like X-Linked Retinitis Pigmentosa (XLRP) and Achromatopsia B3 (ACHMB3) programs. The company said initial operations at the facility are expected to begin in Q4 with GMP capabilities expected to be finalized in Q1 2023. "We expect the facility will also play an important role in support of our promising pipeline of additional clinical and pre-clinical programs," the company said. (AGTC) rose 1.3% premarket.Applied Genetic Technologies proposes stock offering to fund clinical trials
Applied Genetic Technologies (NASDAQ:AGTC) announced Tuesday it plans to initiate underwritten stock offering that will see the issue of its common shares and accompanying stock purchase warrants. The company intends to use the net proceeds for fund its ongoing Skyline and Vista clinical trials in its X-linked retinitis pigmentosa program and its ongoing Phase 1/2 clinical trials in its Achromatopsia program, its preclinical development programs, investments in its manufacturing facility and for working capital and other general corporate purposes, including scheduled payments under its term loan with Hercules Capital, Inc. AGTC Shares fell 29% after-hours, Tuesday, to trade at $0.60. Earlier: Applied Genetic Technologies raised $9.8M in stock offeringRecent updates
Shareholder Returns
| AGTC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.8% | 2.1% | -3.3% |
| 1Y | -80.9% | 25.0% | 22.3% |
Return vs Industry: AGTC underperformed the US Biotechs industry which returned -10.2% over the past year.
Return vs Market: AGTC underperformed the US Market which returned -14.8% over the past year.
Price Volatility
| AGTC volatility | |
|---|---|
| AGTC Average Weekly Movement | 19.5% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AGTC's share price has been volatile over the past 3 months.
Volatility Over Time: AGTC's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 102 | Sue Washer | agtc.com |
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease.
Applied Genetic Technologies Corporation Fundamentals Summary
| AGTC fundamental statistics | |
|---|---|
| Market cap | US$12.62m |
| Earnings (TTM) | -US$70.23m |
| Revenue (TTM) | US$325.00k |
Is AGTC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGTC income statement (TTM) | |
|---|---|
| Revenue | US$325.00k |
| Cost of Revenue | US$21.76m |
| Gross Profit | -US$21.44m |
| Other Expenses | US$48.80m |
| Earnings | -US$70.23m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.19 |
| Gross Margin | -6,596.62% |
| Net Profit Margin | -21,610.46% |
| Debt/Equity Ratio | 92.6% |
How did AGTC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/12/01 20:02 |
| End of Day Share Price | 2022/11/30 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2022/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Applied Genetic Technologies Corporation is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Birchenough | BMO Capital Markets Equity Research |
| Yun Zhong | Brean Capital Historical (Janney Montgomery) |
| Yun Zhong | BTIG |